FV03 MEK Inhibitors improved the Survival of NRAS-mutated Melanoma Patients by using Checkpoint Inhibitors: Results of a retrospective, multicenter Analysis of 364 Patients
Kirchberger MC, Ugurel S, Mangana J, Heppt M, Eigentler T, Berking C, Schadendorf D, Schuler G, Dummer R, Heinzerling L (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Book Volume: 16
Pages Range: 4-4
Authors with CRIS profile
Gerold Schuler
Lehrstuhl für Haut- und Geschlechtskrankheiten
Lucie Heinzerling
Department of Dermatology
Involved external institutions
Universitätsklinikum Tübingen
Germany (DE)
Universitätsklinikum der Ludwig-Maximilians-Universität München
Germany (DE)
Universitätsspital Zürich (USZ)
Switzerland (CH)
Universitätsklinikum Essen
Germany (DE)
Germany (DE)
Universitätsklinikum der Ludwig-Maximilians-Universität München
Germany (DE)
Universitätsspital Zürich (USZ)
Switzerland (CH)
Universitätsklinikum Essen
Germany (DE)
How to cite
APA:
Kirchberger, M.C., Ugurel, S., Mangana, J., Heppt, M., Eigentler, T., Berking, C.,... Heinzerling, L. (2018). FV03 MEK Inhibitors improved the Survival of NRAS-mutated Melanoma Patients by using Checkpoint Inhibitors: Results of a retrospective, multicenter Analysis of 364 Patients. (pp. 4-4).
MLA:
Kirchberger, M. C., et al. "FV03 MEK Inhibitors improved the Survival of NRAS-mutated Melanoma Patients by using Checkpoint Inhibitors: Results of a retrospective, multicenter Analysis of 364 Patients." 2018. 4-4.
BibTeX: Download